needed effects
dolutegravir
active ingredient
tivicay
unwanted side effects
medical attention
dolutegravir side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
discontinuation
side effects
therapy-naive patients
therapy-experienced integrase strand transfer inhibitor
insti
naive patients
therapy-experienced insti-experienced patients
diarrhea
nausea
elevated lipase
abdominal pain
abdominal discomfort
flatulence
upper abdominal pain
vomiting
grade
grade
elevations in lipase
therapy-naive patients
elevated lipase
therapy-experienced insti-experienced patients
hyperglycemiafrequency
fasted lipid values
including cholesterol
hdl cholesterol
ldl cholesterol
triglycerides
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
grade
grade hyperglycemia
therapy-naive patients
hyperglycemia
elevated cholesterol
therapy-experienced insti-experienced patients
redistribution/accumulation of body fat
antiretroviral therapy
causality
insomnia
abnormal dreams
grade
grade
elevations in ast
therapy-naive patients
grade
grade
elevations in alt
therapy-naive patients
grade
grade
elevations in total bilirubin
therapy-naive patients
elevated alt
ast
therapy-experienced insti-experienced patients
rates of ast
alt abnormalities
higher patients
hepatitis b
c virus
alt abnormalities
grade
hepatitis b
c
patients
hiv
monoinfected patients
mg
day
mg
day
liver chemistry elevations
immune reconstitution syndrome
patients with hepatitis b
c at the start of dolutegravir
active ingredient
tivicay
therapy
antihepatitis therapy
elevated ast
elevated alt
elevated total bilirubin
hepatitisfrequency
liver chemistry elevations
immune reconstitution syndrome
grade
grade
elevations in creatine kinase
therapy-naive patients
elevated creatine kinase
myositis
grade
grade
reductions in total neutrophils
therapy-naive patients
hematology laboratory abnormality
grade
therapy-experienced insti-experienced patients
neutropenia
decreased total neutrophils
hematology laboratory abnormality
headache
dizziness
pruritus
rash
rash
generalized rash
macular rash
maculopapular rash
pruritic rash
drug eruption
increased serum creatinine
inhibition of tubular secretion of creatinine
affecting
affecting renal glomerular function
increased serum creatinine
first weeks of therapy
weeks
mean change of mg/dl
range
mg/dl
weeks of therapy in therapy-naive patients
renal impairmentfrequency
increased serum creatinine
inhibition of tubular secretion of creatinine
fatigue
hypersensitivity reactions
rash
constitutional findings
organ dysfunction
including liver injury
immune reconstitution syndrome
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
side effects of tivicay
fda
healthcare professional for medical advice
black, tarry stools
blistering
peeling skin
bloody urine
burning
itching eyes
chest pain
chills
cough
dark urine
decreased frequency
amount of urine
discharge
excessive tearing
fever
general feeling of discomfort
illness
general tiredness
weakness
increased thirst
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
light-colored stools
loss of appetite
side pain
muscle
joint aches
nausea and vomiting
difficult urination
rash with fever
redness
pain
swelling of the eye
eyelid
inner lining of the eyelid
severe rash
sore throat
sores
ulcers
white spots on the lips
mouth
swelling of the face
fingers
lower legs
swollen glands
troubled breathing
unusual bleeding
bruising
unusual tiredness
weakness
stomach pain
weight gain
yellow eyes
skin
stomach pain
discomfort
headache
itching skin
trouble sleeping
abnormal dreams
diarrhea
dizziness
weight
neck
breast
face
waist